on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics Appoints Thomas Gidoin as CFO
OSE Immunotherapeutics, a French biotech company, has appointed Thomas Gidoin as its new Chief Financial Officer. Gidoin, who brings over 15 years of experience in international finance, joins the Executive Committee of the company. He previously held CFO positions at Advesya and GenSight Biologics, where he led the financial strategy through critical phases, including a successful IPO.
Nicolas Poirier, CEO of OSE Immunotherapeutics, emphasized the significance of Gidoin's expertise in biotech capital markets to advance the company's late-stage assets. Gidoin expressed enthusiasm about joining the team, highlighting the company's potential with its innovative research platform and late-stage assets in oncology and inflammation.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news